Mark T. Finn

Mark Finn

Chairman & CEO

Biography: 

Mark has over 45 years of investment experience and has devoted his entire professional career to providing investment services to the business community. In the mid-seventies he joined the predecessor to Vantage Consulting Group as a consultant and was asked to serve as its Chairman and Chief Executive Officer in 1986, a capacity in which he continues to serve today. Mark shares responsibility with the CIO for the development of investment strategy and leads the firm's discovery and due diligence on new investment managers and strategies. Mark began his career at Virginia National Bank in 1968 where he rose to Trust Executive Officer and Chief Investment Officer. In 1983 he became a member of the State of Virginia Retirement Plan’s Investment Advisory Committee and served as its Chairman from 1990 through 1994. From 1984 through 1994, he also served on the Board of Trustees of the Virginia Retirement System. From 1990 through 1994, he served the Alaska State Retirement System and was Chairman of the Investment Operations Advisory Committee from 1993 through 1994. He was a member of the Chicago Mercantile Exchange’s Advisory Committee on Managed Futures and, from 1996 through 2000, was a member of an advisory board to Rowan & Blewitt Incorporated, an international consulting firm. He served as the Vice Chairman and Chief Operating Officer for Lindner Asset Management from 1999 through 2001. Currently, he serves as an Independent Director on the Legg Mason Partners Fund Board. He currently serves on the board of Cibus Global, a biotechnology firm focused on non-transgenic agricultural crop breeding. Mark has taught investments at the University of Virginia’s Darden School of Business and served for nearly two decades on the adjunct faculty at the Mason School of Business at the College of William & Mary, where he also received his MBA. Mark currently serves on the board of managers of the Managing Member of New Ventures I, LLC a venture capital fund investing in biotechnology related entities, and New Ventures Select, LLC, a pharmaceutical royalty fund.

Publications: 

Articles and Book Chapters

“The Triumph of Hope Over Long-run Experience,” Just One Thing. Ed. John Mauldin. New York, NY: Wiley, 2005. 27-43. (with J. Finn)
"Equity Mispricing: It’s Mostly on the Short Side," Financial Analysts Journal, November/December, 1999. (with R. Fuller and J. Kling)
"Market Neutral Investing," Journal of Financial Planning, September 1998
"Creating ‘Optimally Complex’ Models for Forecasting," Financial Analysts Journal, January-February 1991 (with J. Elder IV)
"Investment Performance of an Extreme Value Market Timing Approach," Journal of Financial Planning, vol. 3, no. 1, 1990. (with J. Stevens)
The Computer Revolution," Pensions & Investment Age, September 13, 1982
"Portfolio Objective: Win big, lose little!," Journal of Portfolio Management, Summer 1982 (with R. Vandell)

Abstracts

"Price-to-Book Valuation Models: Do Equity Measurement Procedures Make a Difference?" Presented at the Eastern Finance Association annual meeting, April, 1988, Bal Harbour, Florida. (with J. Haltiner and R. Hayes)
"Justified
Price to Book: A Value Oriented Stock Selection Strategy," Presented at the Eastern Finance Association annual meeting, April 1986, Baltimore, Maryland. (with J. Haltiner)

Textbooks

Cases in Portfolio Management, R. D. Irwin Publishers, 1988. (with R. Vandell)
Teaching Notes to Accompany Cases in Portfolio Management, R. D. Irwin Publishers, 1988. (with R. Vandell)